IDH2 is a novel diagnostic and prognostic serum biomarker for non-small-cell lung cancer

Jiang-jiang Li1,2,3,4, Ruilei Li5, Wenxiang Wang6, Bihua Zhang6, Xin Song5, Chunfang Zhang7, Yang Gao7, Qianjin Liao8, Ya He1,2,3, Shuo You9, Zheqiong Tan1,2,3, Xiangjian Luo1,2,3, Yuehuo Li1,2,3, Min Tang1,2,3, Xinxia Weng1,2,3, Wei Yi1,2,3, Shifang Peng10, Shaohui Liu11, Ying Tan11, Ann M. Bode12 and Ya Cao1,2,3,4,13

1 Key Laboratory of Carcinogenesis and Invasion, Chinese Ministry of Education, Xiangya Hospital, Central South University, Changsha, China
2 Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, China
3 Key Laboratory of Carcinogenesis, Chinese Ministry of Health, Changsha, China
4 Research Center for Technologies of Nucleic Acid-Based Diagnostics and Therapeutics Hunan Province, Changsha, China
5 Cancer Biotherapy Center, The Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming, China
6 The 2nd Department of Thoracic Surgery, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
7 Department of Thoracic Surgery, Xiangya Hospital, Central South University, Changsha, China
8 Key Laboratory of Translational Radiation Oncology, Hunan Province, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
9 Second Affiliated Hospital of Xiangya, Central South University, Changsha, China
10 Department of Infectious Disease, Xiangya Hospital, Central South University, Changsha, China
11 Health Management Center, Xiangya Hospital, Central South University, Changsha, China
12 The Hormel Institute, University of Minnesota, Austin, MN, USA
13 National Joint Engineering Research Center for Genetic Diagnostics of Infectious Diseases and Cancer, Changsha, China

Keywords
IDH2; non-small-cell lung cancer; serum biomarker

Correspondence
Y. Cao, Key Laboratory of Carcinogenesis and Invasion, Chinese Ministry of Education, Xiangya Hospital, Central South University, Changsha 410078, China Tel: +86-731-84805448 E-mail: ycao98@vip.sina.com.

(Received 27 June 2017, revised 7 February 2018, accepted 7 February 2018, available online 25 March 2018)

doi:10.1002/1878-0261.12182

Lung cancer is the most common leading cause of cancer-related death worldwide. Late diagnosis contributes to a high mortality rate and poor survival of this cancer. In our previous study, we found that IDH2 polymorphism rs11540478 is a risk factor for lung cancer. Here, we examined IDH2 protein expression in culture medium in which two non-small-cell lung cancer (NSCLC) cell lines, H460 and A549, were growing. We found that the IDH2 protein was elevated in the culture supernatant fraction in a time- and cell number-dependent manner. Next, we used ELISA methods to examine IDH2 protein level in serum from patients with NSCLC and healthy controls. We found that IDH2 protein levels in serum could distinguish NSCLC patients from healthy controls with an AUC (area under the curve) of 0.83 (95% confidence interval = 0.79–0.88). The IDH2 level was decreased in serum from NSCLC postsurgical patients compared with the paired presurgical serum. High serum IDH2 levels appear to correlate with poor survival in patients with NSCLC. These results suggest that IDH2 levels in the serum could be a new effective biomarker for the diagnosis and prognosis of NSCLC.

Abbreviations
ELISA, enzyme-linked immunosorbent assay; IDH2, isocitrate dehydrogenase 2; NSCLC, non-small-cell lung cancer.
1. Introduction

Lung cancer is the leading cause of cancer-related death worldwide (Jemal et al., 2011). Lung cancer has a high mortality rate, which is usually ascribed to late diagnosis (Siegel et al., 2012). Late diagnosis also contributes to poor survival of patients with lung cancer (Siegel et al., 2012). Age-standardized one-year net survival at diagnosis is about 80% in TNM stage I and 20% in TNM stage III non-small-cell lung cancer (NSCLC) patients (Walters et al., 2013). The five-year relative survival rates of localized patients with lung and bronchus cancer are about 50%, while for patient with distant metastasis is 4% (Siegel et al., 2016). Thus, early diagnosis could greatly reduce mortality rates and increase survival of patients with lung cancer (Ehmann et al., 2012).

Isocitrate dehydrogenase 2 (IDH2) is an enzyme that catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate. IDH2 is mainly located in mitochondrial and extracellular exosomes (http://www.genecards.org). Recently, gain-of-function mutations of the isocitrate dehydrogenase 1/2 (IDH) enzymes have been found in multiple cancers (Clark et al., 2016; Flavahan et al., 2016; Zou et al., 2015). IDH1/2 mutations could produce the ‘onco-metabolite’, 2-hydroxyglutarate (2-HG) from α-ketoglutarate (α-KG) to competitively inhibit α-KG-dependent dioxygenases to activate oncogenes and regulate the expression of multiple genes (Ward et al., 2010; Xu et al., 2011). IDH1/2 inhibitors, such as enasidenib (AG-221), have been used in more than 11 clinical trials and have shown positive results (Burris et al., 2015; Dinardo et al., 2015; Fujii et al., 2016; Mondesir et al., 2016).

Wild-type IDH1/2 was shown to contribute to cell growth and survival. It could carboxylate α-ketoglutarate from glutamine in hypoxia and play a role in cell growth and viability, and it was required for lipogenesis in hypoxic melanoma cells (Filipp et al., 2012; Wise et al., 2011). Glucose and glutamine are the main nutrients utilized for proliferation and NADPH production in cancer cells and can be controlled by oncogenes such as K-ras and c-myc (Cao et al., 2011; DeBerardinis et al., 2007; Liu et al., 2013; Pavlova and Thompson, 2016; Tan et al., 2016; Xiao et al., 2014; Yu et al., 2017). Wild-type IDH2 participated in reductive carboxylation of glutamine to support redox homeostasis during anchorage-independent tumor spheroid formation (Jiang et al., 2016). In our previous study, we showed that idh2 rs11540478 is a risk factor for lung cancer (Li et al., 2017).

In this study, we first analyzed the protein expression of IDH2 in cell culture medium in which two lung cancer cell lines, NCI-H460 and A549, were growing and found that the IDH2 level is increased in a time- and cell number-dependent manner. Further, ELISA methods were employed to examine the level of IDH2 in the serum of 296 patients with non-small-cell lung cancer and 380 healthy control subjects. We found that the level of IDH2 in serum can differentiate lung cancer patients from healthy controls with an AUC of 0.83 (95% confidence interval = 0.79 to 0.88). The protein level of IDH2 levels was shown to be an indicator of poor survival in patients with NSCLC and decreased after the surgical removal of primary tumors. Overall, these results suggested that serum IDH2 could be a new and reliable biomarker for the diagnosis and prognosis of non-small-cell lung cancer.

2. Materials and methods

2.1. Study design

The study subjects included 200 patients with NSCLC and 380 healthy control subjects who were recruited between 2013 and 2016 from Xiangya Hospital of Central South University and The Third Affiliated Hospital of Kunming Medical University, and 96 patients with NSCLC who were recruited between 2015 and 2017 from Hunan Cancer Hospital. Clinical histopathology confirmed all samples were NSCLC (183 adenocarcinomas and 113 squamous carcinomas) and control subjects were verified to be healthy, based on chest X-rays, liver function tests, and blood tumor marker analysis. Surgery is the only treatment provided for the patients with NSCLC, 296 serum samples were collected before surgery, and 29 available serum samples were collected 1 week postsurgery. The study protocol was approved by the ethical review committees of the three hospitals. All clinical data including smoking status were obtained from the hospital pathologic records (Table 1).

2.2. ELISA

NCI-H460 (HTB-177), A549 (CCL-185), HCT116 (CCL-247), and HT29 (HTB-38) were cultured in RPMI 1640 with 10% FBS. Cells were grown in a 37 °C incubator with 5% CO₂ and seeded into 6-well plates. Culture medium was centrifuged at 3000 g for 10 min, and the supernatant was stored at −80 °C.

Serum samples obtained from patients with NSCLC and healthy control subjects were collected using serum separator tubes and centrifuged at 3000 g for
Table 1. Distribution of selected clinical characteristics of NSCLC patients and healthy control subjects.

| Variable                  | Lung cancer patients (%) | Control subjects (%) | P*  |
|---------------------------|--------------------------|----------------------|-----|
| Age (years)              |                          |                      |     |
| 30–50                    | 50 (16.9)                | 90 (23.6)            | 0.09|
| 51–70                    | 205 (69.3)               | 263 (69.2)           |     |
| >70                      | 41 (13.9)                | 27 (7.1)             |     |
| Sex                      |                          |                      |     |
| Female                   | 133 (44.9)               | 174 (45.8)           | 0.79|
| Male                     | 163 (55.1)               | 206 (54.2)           |     |
| TNM stage                |                          |                      |     |
| Ia                       | 200 (67.6)               |                      |     |
| I1a                      | 48 (16.2)                |                      |     |
| Iib                      | 38 (12.8)                |                      |     |
| Iib                      | 10 (3.4)                 |                      |     |
| Histology type           |                          |                      |     |
| Adenocarcinoma           | 183 (61.8)               |                      |     |
| Squamous carcinoma       | 113 (38.2)               |                      |     |
| Smoking status           |                          |                      |     |
| Smokers                  | 134 (45.3)               | 101 (28.9)           | 0.001|
| Nonsmokers               | 162 (54.7)               | 249 (71.1)           |     |
| Unknown                  | 30                       |                      |     |

*Two-sided χ² test.

10 min within 4 h. The supernatant was stored at −80 °C before the final analysis. Serum IDH1/2 assays were performed using a commercially available ELISA kit (SEH839Hu, SEH838Hu 96 Test, Cloud-Clone) according to the manufacturer’s recommendations. The samples and kit components were stored at 4 °C or −20 °C and brought to room temperature before the assay was conducted. Serum samples in standard diluent of a total 100 μL volume were added to the wells of an ELISA analysis plate and covered with a plate sealer and then incubated for 2 h at 37 °C. The liquid was removed, and dilution solution A containing secondary antibodies was added and incubated for 1 h at 37 °C. The plate was washed with buffer 3 times, and then, dilution solution B containing hydrogen peroxide was added and the plate incubated for 30 min. After another five washes with buffer, the substrate 3,3,5,5-tetramethylbenzidine was added and the plated incubated for an additional 15 min. The stop solution sulfuric acid was added, and the absorbance was immediately measured at 450 nm on a plate reader (BioTek). The concentration of IDH1/2 was calculated using a quadratic polynomial fitting curve.

2.3. Statistical analyses

The differences between IDH2 levels in the cell culture medium were analyzed by Student’s t-test. The differences between IDH2 levels in serum samples were evaluated by the Mann–Whitney U-test using continuous variables and nonparametric analyses included in GraphPad Prism Windows (version 5). Receiver operating characteristic (ROC) analysis and Cox regression model were performed using SPSS Windows (version 19.0).

3. Results

3.1. IDH1/2 level in cancer cell culture medium

IDH2 is mainly located in mitochondrial and extracellular exosomes. The high expression of IDH2 in lung cancer cells and the location of IDH2 suggested that IDH2 might be secreted out of the cells. We analyzed the expression level of the IDH2 protein in cell culture medium in which H460 and A549 NSCLC cells were grown. We found that the levels of IDH2 protein in the culture media from of either cell line increased with culture time (from 24 to 72 h, P < 0.01, Fig. 1A) or with increasing cell number (from 1 × 10⁵ to 4 × 10⁵, P < 0.01, Fig. 1B). The levels of IDH2 protein increased in HCT116 and HT29 cell culture media (P < 0.05, Fig. 1C). The release of IDH2 is not specific to NSCLC, but it could also occur in other cancer cell lines, such as colon cancer cell lines HCT116 and HT29. To determine whether the enzyme secretion/release is isozyme-specific, we measured IDH1 protein in cultured medium of H460 and A549 cells, which was found to be elevated with cell number (P < 0.01, Fig. 1D).

3.2. The level of IDH2 in serum from patients with NSCLC and healthy control subjects

We next recruited a total of 676 participants (including 296 patients with NSCLC and 380 healthy controls, as shown in Table 1). The patients with NSCLC and healthy controls were divided into a training set (96 patients with NSCLC from Hunan province and 130 healthy controls) and a test set (200 patients with NSCLC from Yunnan province and 250 healthy controls).

In the training set, the median level of IDH2 in the serum from patients with NSCLC was 12.50 ± 8.16 ng·mL⁻¹, which was significantly higher than that of the healthy controls (6.57 ± 5.10 ng·mL⁻¹; Fig. 2A; P < 0.0001, Mann–Whitney U-test). The level of IDH2 was also higher in serum from patients with lung adenocarcinoma and squamous cell carcinoma compared with healthy control subjects, but was similar between the two histologic patient groups (Fig. 2A).
In the test set, the median level of IDH2 in the serum from patients with NSCLC was 12.84 ± 7.42 ng·mL⁻¹, which was also significantly higher than that of the healthy controls (4.97 ± 3.90 ng·mL⁻¹; Fig. 2B; P < 0.0001, Mann–Whitney U-test). The level of IDH2 was also higher in serum from patients with lung adenocarcinoma and squamous cell carcinoma compared with healthy control subjects, but was similar between the two histologic patient groups (Fig. 2B).

In the whole set, the median level of IDH2 in the serum from patients with NSCLC was 12.53 ± 7.76 ng·mL⁻¹, which was significantly higher than that of the healthy controls (6.48 ± 4.29 ng·mL⁻¹; Fig. 2C; P < 0.0001, Mann–Whitney U-test). The level of IDH2 was also higher in serum from patients with lung adenocarcinoma and squamous cell carcinoma compared with healthy control subjects, but was similar between the two histologic patient groups (Fig. 2C).

Age, gender, and smoking status for both patients and healthy controls were analyzed by Mann–Whitney U-test, and there is no correlation between smoking status and serum IDH2 protein levels both in patients with lung cancer and healthy controls (P > 0.05). There is also no correlation between serum IDH2 protein levels and age, gender, tumor stage (P > 0.05).

3.3. ROC analyses of IDH2 in patients with NSCLC and healthy control subjects

Next, ROC curves based on the ELISA results were plotted to assess the potential use of serum IDH2 as a noninvasive biomarker for the diagnosis of patients with NSCLC. Results indicated that the protein level of IDH2 in serum could differentiate the patient with lung cancer from the healthy control subject. We selected an optimum IDH2 cutoff value based on the Youden’s J statistic (Youden’s index = sensitivity + specificity-100%) for the diagnosis of patients with NSCLC (Ruopp et al., 2008).

In the training set, the cutoff value was 10.16. The AUC of lung adenocarcinoma was 0.82 (95% CI = 0.79 to 0.88), with a sensitivity of 84.4% and specificity of 78.6% (Fig. 3A). The AUC of lung squamous carcinoma was 0.80 (95% CI = 0.76 to 0.84), with a sensitivity of 80.2% and specificity of 75.2% (Fig. 3A).

In the test set, the cutoff value was 8.34. The AUC of lung adenocarcinoma was 0.82 (95% CI = 0.76 to 0.89), with a sensitivity of 76.6% and specificity of 63.3% (Fig. 3B). The AUC of lung squamous carcinoma was 0.88 (95% CI = 0.81 to
0.95), with a sensitivity of 83.2% and specificity of 79.3% (Fig. 3B).

In the whole set, the cutoff value was 9.51. The AUC of lung adenocarcinoma was 0.82 (95% CI = 0.78 to 0.86), with a sensitivity of 81.5% and specificity of 76.8% (Fig. 3C). The AUC of lung squamous carcinoma was 0.85 (95% CI = 0.81 to 0.89), with a sensitivity of 82.2% and specificity of 77.6% (Fig. 3C). The AUC of patient with NSCLC was 0.83 (95% CI = 0.79 to 0.88), with a sensitivity of 82.1% and specificity of 77.2% (Fig. 3C).

3.4. Comparison of IDH2 levels in serum from pre- and postsurgical patients with NSCLC

Surgery is the primary treatment for the TNM stage I and stage II NSCLC patients. We found a level of IDH2 at 7.26 ± 3.98 ng·mL⁻¹ in serum from patients with NSCLC at 1 week after surgery, which was significantly lower than level before surgery (11.27 ± 3.51 ng·mL⁻¹, P < 0.0001, Mann–Whitney U-test, Fig. 4A) and approached the level of that observed...
in healthy control subjects (6.57 ± 5.10 ng·mL⁻¹, \(P = 0.91\), Mann–Whitney U-test; Fig. 4B).

3.5. The association between serum IDH2 levels and overall survival of patients with NSCLC

Next, we examined the association between serum IDH2 levels with overall survival of patients with NSCLC by performing the Kaplan–Meier survival analysis. We found that patients with higher levels of postsurgical serum IDH2 level had significantly worse overall survival rates (\(P = 0.042\); log-rank test; Fig. 5). The follow-up time of these 126 patients was from 10 months to 48 months, with a medium time of 32 months. The Cox regression equation was employed to identify the potential factors that affect overall survival of patient with NSCLC. Male patients were found to survive significantly shorter than female (HR = 0.96, 95% CI = 0.92–0.99, \(P = 0.025\)).

4. Discussion

Computed tomographic (CT) scans are the most commonly used clinical diagnosis methods for lung cancer, but have some significant limitations, including false-positive results and over-diagnosis (Bach et al., 2012; Patz et al., 2014; Wender et al., 2013). Serum protein levels are also used for diagnosing lung cancer. The commonly used clinical serum biomarkers are CEA, CA125, CYFRA 21-1, SCC, and NSE, but all are not specific (Hanash et al., 2011; Molina et al., 2003; Niewoehner and Rubins, 2003). Lactate dehydrogenase B in serum was shown to be correlated with the clinical stage of lung cancer (Chen et al., 2006). Recently, IDH1 was reported to be up-regulated in lung cancer tissues and could serve as novel plasma biomarker for the diagnosis of non-small-cell lung cancer (Sun et al., 2013; Tan et al., 2012). None of the published candidate biomarkers for lung cancer diagnosis are yet ready for clinical use (Hassanein et al., 2012).

In a previous study, we showed that a new \(IDH2\) genetic variant rs11540478 is associated with a risk of lung cancer. Functional analysis showed higher \(IDH2\) expression and increasing cell viability among T alleles; \(IDH2\) mRNA was higher in peripheral blood lymphocytes from patients with lung cancer compared to healthy control subjects (Li et al., 2017). Here, we found that the IDH2 protein was elevated in a time- and cell number-dependent manner in the culture medium in which lung cancer cells were grown. This suggested that IDH2 might be a protein secreted either in the extracellular exosomes or by other mechanism.

Exosomes can be released by all types of cells, and it is one of the media that cancer cells used to communicate with its neighbor or distant cells, cancer-associated exosomes can promote tumor growth and invasive (Hoshino et al., 2013; Raimondo et al., 2015).
Due to the function of IDH2 protein, IDH2 in the culture medium may promote proliferation and viability of lung cancer cells. In cell culture process, dying cells may release a part of the extracellular IDH1 and IDH2 in a normal cell turnover process. The dying part of tumor tissues may also release IDH1 and IDH2 protein or spread into blood, which may contribute to increasing of serum IDH2 level and a part of the IDH1 and IDH2 detected.

We found that IDH2 was higher in serum from patients with lung cancer compared to healthy control subjects. Analysis showed an AUC of 0.83 (Fig. 3A), which is better than that of current clinically used biomarkers, including CA125, Cyfra21-1, and CEA, and similar to that of IDH1 (Sun et al., 2013). Recently, serum miRNA and metabolomics have been found to be diagnostic and prognostic biomarker for non-small-cell lung cancer. The AUC for miR-652, miR-660, miR-21, and metabolite diacetylspermine (0.74) was 0.82, 0.74, 0.81, and 0.74, respectively, which are nearly similar to that of IDH2 (Wikoff et al., 2015; Zhao et al., 2015; Zhou et al., 2015).

Although the IDH2 levels in patients with NSCLC and healthy controls were significantly different in our study, some overlap was observed between patients and control subjects (Fig. 2). IDH2 can be used as an adjunctive biomarker for diagnosis in lung cancer. Further, the study will also be needed to determine whether serum IDH2 is an accurate biomarker for other cancer types or is specific for NSCLC.

Interestingly, the level of serum IDH2 decreased in patients with NSCLC at about 1 week after surgical removal of the tumor. The level of serum IDH2 was found to be an indicator of poor survival and could serve as a prognostic biomarker for patients with NSCLC. Importantly, it might be served as an effective and accurate biomarker for evaluating the surgical outcome of patients with NSCLC.

5. Conclusions

Late diagnosis contributes to a high mortality rate and poor survival of lung cancer. Here, we found IDH2 protein was elevated in the culture supernatant fraction of lung cancer cells. Serum IDH2 protein could be employed to distinguish patients with NSCLC from healthy controls. High IDH2 levels appeared to correlate with poor survival in patients with NSCLC. These results suggested that serum IDH2 could be a new effective biomarker for the diagnosis and prognosis of NSCLC.

Acknowledgements

This work was supported by The National Basic Research Program of China (No. 2011CB504305) and The Natural Science Foundation of Hunan Province (No. 14JJ3039).

Author contributions

JYL, YH, ZT, XL, YL, MT, XW, and WY performed the experiments. RL, WW, BZ, XS, CZ, YG, QL, SY, SP, SL, and YT recruited the participants. JYL and AMB wrote the manuscript. YC supervised the experiments.

References

Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, Byers T, Colditz GA, Gould MK, Jett JR et al. (2012) Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 307, 2418–2429.

Burris H, Mellinghoff I, Maher E, Wen P, Beeram M, Touat M, Faris J, Azad N, Cloughesy T, Gore L et al. (2015) The first reported results of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a Phase I study of patients with advanced IDH1-mutant solid tumors, including gliomas. Mol Cancer Ther 14(12 Suppl 2), Abstract PL04–PL05.

Cao Y, DePinho RA, Ernst M and Vousden K (2011) Cancer research: past, present and future. Nat Rev Cancer 11, 749–754.

Chen Y, Zhang H, Xu A, Li N, Liu J, Liu C, Lv D, Wu S, Huang L, Yang S et al. (2006) Elevation of serum l-lactate dehydrogenase B correlated with the clinical stage of lung cancer. Lung Cancer 54, 95–102.

Clark O, Yen K and Mellinghoff IK (2016) Molecular pathways: isocitrate dehydrogenase mutations in cancer. Clin Cancer 22, 1837–1842.

DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S and Thompson CB (2007) Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 104, 19345–19350.

Dinardo C, de Botton S, Pollyea D, Stein E, Fathi A, Roboz G, Collins R, Swords R, Flinn I, Altman J et al. (2015) Molecular profiling and relationship with clinical response in patients with idh1 mutation-positive hematologic malignancies receiving AG-120, a first-in-class potent inhibitor of mutant IDH1, in addition to data from the completed dose escalation portion of the phase 1 study. Blood 126(23S), Abstract 1306.

Ehmann R, Boedecker E, Friedrich U, Sagert J, Dippon J, Friedel G and Walles T (2012) Canine scent detection
in the diagnosis of lung cancer: revisiting a puzzling phenomenon. Eur Respir J 39, 669–676.

Filipp FV, Scott DA, Ronai ZA, Osterman AL and Smith JW (2012) Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells. Pigment Cell Melanoma Res 25, 375–383.

Flavahan WA, Drier Y, Liu BB, Gillespie SM, Venteicher AS, Stemmer-Rachamimov AO, Suva ML and Bernstein BE (2016) Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature 529, 110–114.

Fujii T, Khawaja MR, DiNardo CD, Atkins JT and Janku F (2016) Targeting isocitrate dehydrogenase (IDH) in cancer. Discov Med 21, 373–380.

Hanash SM, Baik CS and Kallioniemi O (2011) Emerging molecular biomarkers–blood-based strategies to detect and monitor cancer. Nat Rev Clin Oncol 8, 142–150.

Hassanein M, Callison JC, Callaway-Lane C, Aldrich MC, Hoshino D, Kirkbride KC, Costello K, Clark ES, Sinha S, Jemal A, Bray F, Center MM, Ferlay J, Ward E and Jiang L, Shestov AA, Whitcomb BW and Schisterman EF (2008) Youden Index and optimal cut-point estimated from observations affected by a lower limit of detection. Biom J 50, 419–430.

Siegel RL, Miller KD and Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66, 7–30.

Siegel R, Naishadham D and Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62, 10–29.

Sun N, Chen Z, Tan F, Zhang B, Yao R, Zhou C, Li J, Gao Y, Liu Z, Tan X et al. (2013) Isocitrate dehydrogenase 1 is a novel plasma biomarker for the diagnosis of non-small cell lung cancer. Clin Cancer Res 19, 5136–5143.

Tan F, Jiang Y, Sun N, Chen Z, Lv Y, Shao K, Li N, Qiu B, Gao Y, Li B et al. (2012) Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis. Mol Cell Proteomics 11, M111 008821.

Tan Z, Luo X, Xiao L, Tang M, Bode AM, Dong Z and Cao Y (2016) The role of PGC1alpha in cancer metabolism and its therapeutic implications. Mol Cancer Ther 15, 774–782.

Walters S, Marinie C, Coleman MP, Peake MD, Butler J, Young N, Bergstrom S, Hanna L, Jakobsen E, Kolbeck K et al. (2013) Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007. Thorax 68, 551–564.

Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Collier HA, Cross JR, Fantin VR, Hedvat CV, Perl AE et al. (2010) The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17, 225–234.

Wender R, Fontham ET, Barrera E Jr, Colditz GA, Church TR, Ettinger DS, Etzioni R, Flowers CR, Gazelle GS, Kelsey DK et al. (2013) American Cancer Society lung cancer screening guidelines. CA Cancer J Clin 63, 107–117.
IDH2 is potential biomarker for NSCLC

Wikoff WR, Hanash S, DeFelice B, Miyamoto S, Barnett M, Zhao Y, Goodman G, Feng Z, Gandara D, Fiehn O et al. (2015) Diacetylspermine is a novel prediagnostic serum biomarker for non-small-cell lung cancer and has additive performance with pro-surfactant protein B. J Clin Oncol 33, 3880–3886.

Wise DR, Ward PS, Shay JE, Cross JR, Gruber JJ, Sachdeva UM, Platt JM, DeMatteo RG, Simon MC and Thompson CB (2011) Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci USA 108, 19611–19616.

Xiao L, Hu ZY, Dong X, Tan Z, Li W, Tang M, Chen L, Yang L, Tao Y, Jiang Y et al. (2014) Targeting Epstein-Barr virus oncoprotein LMP1-mediated glycosylation sensitizes nasopharyngeal carcinoma to radiation therapy. Oncogene 33, 4568–4578.

Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT et al. (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 19, 17–30.

Yu X, Li W, Deng Q, You S, Liu H, Peng S, Liu X, Lu J, Luo X, Yang L et al. (2017) Neoalbaconol inhibits angiogenesis and tumor growth by suppressing EGFR-mediated VEGF production. Mol Carcinog 56, 1414–1426.

Zhao W, Zhao JJ, Zhang L, Xu QF, Zhao YM, Shi XY and Xu AG (2015) Serum miR-21 level: a potential diagnostic and prognostic biomarker for non-small cell lung cancer. Int J Clin Exp Med 8, 14759–14763.

Zhou C, Chen Z, Dong J, Li J, Shi X, Sun N, Luo M, Zhou F, Tan F and He J (2015) Combination of serum miRNAs with Cyfra21-1 for the diagnosis of non-small cell lung cancer. Cancer Lett 367, 138–146.

Zou Y, Bai HX, Wang Z and Yang L (2015) Comparison of immunohistochemistry and DNA sequencing for the detection of IDH1 mutations in gliomas. Neuro Oncol 17, 477–478.

Molecular Oncology 12 (2018) 602–610 © 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.